ERBB2 and breast carcinoma: Given that most women 50 and older with node‐negative pT1‐2N0 HR+/HER2‐BC are unlikely to benefit significantly from adjuvant chemotherapy alone, accurately identifying which node‐negative patients in this age group with HR+ breast cancer would benefit from adjuvant CET becomes crucial.22